期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021; 22 (7)
Opinion statement Intravenous administration of fluoropyrimidine-based chemotherapy has been the backbone of treatment in colorectal cancer (CRC) for ......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021; 22 (2)
Opinion Statement In the advanced cancer setting, patients, families, and clinicians are often confronted with an uncertain future regarding treatment......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020; 21 (4)
Opinion statement The MET exon 14 skipping mutation is found in approximately 3% of lung adenocarcinomas and slightly more than 2% of lung squamous ce......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019; 20 (12)
Opinion statement Malignancies arising in midline brain structures, including lymphomas, teratomas, germinomas, diffuse midline gliomas, and medullobl......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018; 19 (12)
Opinion statement Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metas......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018; 19 (11)
Opinion statementNon-small cell lung cancer (NSCLC) harboring epidermal growth receptor (EGFR) mutation has distinct genomic characteristics. Introduc......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (11)
Opinion statement Autophagy is a physiological process that occurs in normal tissues. Under external environmental pressure or internal environmental ......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (7)
Opinion statement The current standard treatment for locally advanced rectal cancer is based on a multimodal comprehensive treatment combined with pre......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (10)
Opinion statement Melanoma is one of the deadliest malignancies. Its incidence has been significantly increasing in most countries in recent decades. ......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (11)
Opinion statement Melanoma is caused by a variety of somatic mutations, and among these mutations, BRAF mutation occurs most frequently and has routin......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (12)
Opinion statement Immunotherapy is revolutionizing tumor treatment by activating the immune response to tumors. Among them, immunotherapy represented ......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (2)
Opinion statement Cutaneous angiosarcoma is a rare and invasive malignant tumor. For localized cAS patients, wide-margin excision was recommended. Due......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (1)
Opinion statement Malignant tumors of the external auditory canal (EAC) are rare tumors in the head and neck. Delayed diagnosis is not uncommon becaus......
期刊： CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022; 23 (4)
Opinion statement Informal caregivers invest a significant amount of time and effort to provide cancer patients with physical, psychological, informat......
